WASHINGTON — Food and Drug Administration Commissioner Scott Gottlieb on Wednesday accused drug makers who manufacture pricey biologic medicines of using “unacceptable” anti-competitive tactics to keep competitors off the market, costing Americans billions.

The tactics — some of which Gottlieb will refer to as a “toxin” — have prevented other drug makers from launching biosimilar medicines, highly similar versions of the same drugs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • While this statistic seems compelling – “Americans could have saved $4.5 billion in 2017 if all of the FDA-approved biosimilars were actually available in the United States, ” – something is missing. That savings is computed against what figure and what percentage does that saving represent? If total spend is currently is $450 Billion (2016 figure – CNBC), then 40 pct of that is $180 Billion USD. I will never see $4.5 billion USD personally, so I will agree that’s a lot but it represents a discount of ‘only’ 2.5% – scarcely impressive. Driving that spending level down to $175.5 billion USD doesn’t seem like much – “just sayin’ “

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy